Bryce B Reeve1, Molly McFatrich1, Jennifer W Mack2, Scott H Maurer3, Shana S Jacobs4, David R Freyer5, Janice S Withycombe6, Justin N Baker7, Sharon M Castellino8, Li Lin1, Nicole R Lucas1, Pamela S Hinds4. 1. Duke University School of Medicine, 215 Morris St, Suite 230, Durham, NC 27701, USA. 2. Dana-Farber Cancer Institute, Dana 1104, 450 Brookline Avenue, Boston, MA 02215, USA. 3. University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, 4401 Penn Ave, 5th Floor Plaza Bldg, Suite 506, Pittsburgh, PA 15224, USA. 4. Children's National Hospital, 111 Michigan Ave., N.W., Washington, DC 20010, USA. 5. Children's Hospital Los Angeles, 4650 Sunset Blvd, Mail Stop 54, Los Angeles, CA 90027-6016, USA. 6. Clemson University School of Nursing, 508 Edwards, Clemson, SC 29634 [Formerly, Emory University, Atlanta, GA], USA. 7. St. Jude Children's Research Hospital, 262 N Danny Thomas Place, Mail Stop 260, Memphis, TN 38105, USA. 8. Emory University School of Medicine, Children's Healthcare of Atlanta, 2015 Uppergate Drive, ECC 436, Atlanta, GA 30322, USA.
Abstract
BACKGROUND: Patient-reported outcome (PRO) measurements linked to Common Terminology Criteria for Adverse Events (CTCAE) grading may improve symptom adverse event (AE) reporting in pediatric oncology trials. We evaluated construct validity, responsiveness, and test-retest reliability of the Ped-PRO-CTCAE measurement system for children and adolescents undergoing cancer care. METHODS: A total of 482 children and adolescents (7-18 years, 41.5% not non-Hispanic white) newly diagnosed with cancer and their caregivers participated from nine pediatric oncology hospitals. Surveys were completed at 72 hours preceding treatment initiation (T1) and at follow-up (T2) approximately 7-17 days later for chemotherapy, and 4+ weeks for radiation. Psychometric analyses examined the relationship of Ped-PRO-CTCAE items (assessing 62 symptom AEs) with Patient-Reported Outcomes Measurement Information System, Memorial Symptom Assessment Scale, Lansky Play-Performance Scale, and medication use. A separate test-retest study included 46 children. RESULTS: Ped-PRO-CTCAE and Memorial Symptom Assessment Scale were strongly correlated across age groups at T2: 7-12 years (r = 0.62-0.80), 13-15 years (r = 0.44-0.94), and 16-18 years (r = 0.65-0.98); and over time. The Ped-PRO-CTCAE was strongly correlated with Patient-Reported Outcomes Measurement Information System Pediatric measures at T2; for example, pain interference (r = 0.70, 95% confidence interval [CI] = 0.64 to 0.76), fatigue severity (r = 0.63, 95% CI = 0.56 to 0.69), and depression severity (r = 0.76, 95% CI = 0.71 to 0.81). Ped-PRO-CTCAE items differentiated children by Lansky Play-Performance Scale and by medication use. Test-retest agreement ranged from 54.3% to 93.5%. CONCLUSIONS: This longitudinal study provided evidence for the construct validity and reliability of the core Ped-PRO-CTCAE symptom AE items relative to several established measures. Additional responsiveness data with clinical anchors are recommended. Incorporation of Ped-PRO-CTCAE in trials may lead to a better understanding of the cancer treatment experience.
BACKGROUND:Patient-reported outcome (PRO) measurements linked to Common Terminology Criteria for Adverse Events (CTCAE) grading may improve symptom adverse event (AE) reporting in pediatric oncology trials. We evaluated construct validity, responsiveness, and test-retest reliability of the Ped-PRO-CTCAE measurement system for children and adolescents undergoing cancer care. METHODS: A total of 482 children and adolescents (7-18 years, 41.5% not non-Hispanic white) newly diagnosed with cancer and their caregivers participated from nine pediatric oncology hospitals. Surveys were completed at 72 hours preceding treatment initiation (T1) and at follow-up (T2) approximately 7-17 days later for chemotherapy, and 4+ weeks for radiation. Psychometric analyses examined the relationship of Ped-PRO-CTCAE items (assessing 62 symptom AEs) with Patient-Reported Outcomes Measurement Information System, Memorial Symptom Assessment Scale, Lansky Play-Performance Scale, and medication use. A separate test-retest study included 46 children. RESULTS: Ped-PRO-CTCAE and Memorial Symptom Assessment Scale were strongly correlated across age groups at T2: 7-12 years (r = 0.62-0.80), 13-15 years (r = 0.44-0.94), and 16-18 years (r = 0.65-0.98); and over time. The Ped-PRO-CTCAE was strongly correlated with Patient-Reported Outcomes Measurement Information System Pediatric measures at T2; for example, pain interference (r = 0.70, 95% confidence interval [CI] = 0.64 to 0.76), fatigue severity (r = 0.63, 95% CI = 0.56 to 0.69), and depression severity (r = 0.76, 95% CI = 0.71 to 0.81). Ped-PRO-CTCAE items differentiated children by Lansky Play-Performance Scale and by medication use. Test-retest agreement ranged from 54.3% to 93.5%. CONCLUSIONS: This longitudinal study provided evidence for the construct validity and reliability of the core Ped-PRO-CTCAE symptom AE items relative to several established measures. Additional responsiveness data with clinical anchors are recommended. Incorporation of Ped-PRO-CTCAE in trials may lead to a better understanding of the cancer treatment experience.
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet Journal: J Clin Epidemiol Date: 2006-08-24 Impact factor: 6.437
Authors: Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve Journal: Cancer Date: 2019-09-25 Impact factor: 6.860
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Jin-Shei Lai; Brian D Stucky; David Thissen; James W Varni; Esi Morgan DeWitt; Debra E Irwin; Karin B Yeatts; Darren A DeWalt Journal: Qual Life Res Date: 2013-02-02 Impact factor: 4.147
Authors: J J Collins; M E Byrnes; I J Dunkel; J Lapin; T Nadel; H T Thaler; T Polyak; B Rapkin; R K Portenoy Journal: J Pain Symptom Manage Date: 2000-05 Impact factor: 3.612
Authors: Bryce B Reeve; Janice S Withycombe; Justin N Baker; Mary C Hooke; Jessica C Lyons; Catriona Mowbray; Jichuan Wang; David R Freyer; Steven Joffe; Lillian Sung; Deborah Tomlinson; Stuart H Gold; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Pamela S Hinds; Catherine A Billups; Xueyuan Cao; Jami S Gattuso; Elizabeth Burghen; Nancy West; Jeffrey E Rubnitz; Najat C Daw Journal: Eur J Oncol Nurs Date: 2008-10-15 Impact factor: 2.398
Authors: Amy M Berkman; Karly M Murphy; Elizabeth J Siembida; Nancy Lau; Yimin Geng; Susan K Parsons; John M Salsman; Michael E Roth Journal: Value Health Date: 2021-08-08 Impact factor: 5.725
Authors: Meaghann S Weaver; Jichuan Wang; Katie A Greenzang; Molly McFatrich; Pamela S Hinds Journal: Support Care Cancer Date: 2021-10-18 Impact factor: 3.603
Authors: Ethan Basch; Angela M Stover; Deborah Schrag; Arlene Chung; Jennifer Jansen; Sydney Henson; Philip Carr; Brenda Ginos; Allison Deal; Patricia A Spears; Mattias Jonsson; Antonia V Bennett; Gita Mody; Gita Thanarajasingam; Lauren J Rogak; Bryce B Reeve; Claire Snyder; Lisa A Kottschade; Marjory Charlot; Anna Weiss; Deborah Bruner; Amylou C Dueck Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Bryce B Reeve; Molly McFatrich; Li Lin; Nicole R Lucas; Jennifer W Mack; Shana S Jacobs; Janice S Withycombe; Justin N Baker; David R Freyer; Pamela S Hinds Journal: Cancer Date: 2020-12-17 Impact factor: 6.860
Authors: Canhua Xiao; Andrew H Miller; Gang Peng; Morgan E Levine; Karen N Conneely; Hongyu Zhao; Ronald C Eldridge; Evanthia C Wommack; Sangchoon Jeon; Kristin A Higgins; Dong M Shin; Nabil F Saba; Alicia K Smith; Barbara Burtness; Henry S Park; Melinda L Irwin; Leah M Ferrucci; Bryan Ulrich; David C Qian; Jonathan J Beitler; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2021-04-18 Impact factor: 8.013
Authors: Allison Barz Leahy; Lisa A Schwartz; Yimei Li; Bryce B Reeve; Justin E Bekelman; Richard Aplenc; Ethan M Basch Journal: Cancer Date: 2021-05-04 Impact factor: 6.921
Authors: Meena N Murugappan; Bellinda L King-Kallimanis; Gregory H Reaman; Vishal Bhatnagar; Erica G Horodniceanu; Najat Bouchkouj; Paul G Kluetz Journal: J Natl Cancer Inst Date: 2022-01-11 Impact factor: 13.506
Authors: Scott H Maurer; Pamela S Hinds; Bryce B Reeve; Jennifer W Mack; Molly McFatrich; Li Lin; Janice S Withycombe; Shana S Jacobs; Justin N Baker; Sharon M Castellino; David R Freyer Journal: Cancer Date: 2021-07-01 Impact factor: 6.921
Authors: Pamela S Hinds; Meaghann S Weaver; Janice S Withycombe; Justin N Baker; Shana S Jacobs; Jennifer W Mack; Scott H Maurer; Molly McFatrich; Laura C Pinheiro; Bryce B Reeve; Jichuan Wang Journal: J Pain Symptom Manage Date: 2020-10-20 Impact factor: 5.576